0.00
100.00%
-0.60
アフターアワーズ:
.56
0.56
+
Aslan Pharmaceuticals Ltd Adr (ASLN) 最新ニュース
United States shares mixed at close of trade; Dow Jones Industrial Average up 0.59% - Investing.com India
U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.59% - Investing.com
Is ASLAN Pharmaceuticals Ltd ADR (NASDAQ: ASLN) Doomed To Fail? - Stocks Register
Crude Oil Rises 2%; Five Below Shares Plunge - Benzinga
ASLAN Pharmaceuticals Ltd ADR (ASLN) is looking forward to a strong quarter - SETE News
The Future of ASLAN Pharmaceuticals Ltd ADR: Analyzing ASLN - The InvestChronicle
Closing Figures: ASLAN Pharmaceuticals Ltd ADR (ASLN)’s Negative Finish at 1.38, Down -45.88 - The Dwinnex
United States shares higher at close of trade; Dow Jones Industrial Average up 0.53% - Investing.com India
ASLAN Pharmaceuticals faces delisting from Nasdaq - Investing.com
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.53% - Investing.com
Short Interest in ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) Declines By 85.8% - American Banking and Market News
Short Interest in ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) Declines By 85.8% - Defense World
Market Insights: ASLAN Pharmaceuticals Ltd ADR (ASLN)'s Notable Gain of 0.98, Closing at 2.27 – DWinneX - The Dwinnex
ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) Short Interest Down 9.2% in June - Defense World
ASLAN Pharmaceuticals to Host Third Webinar in A⁴ KOL Series: 'Dialogues With International Thought Leaders in ... - Barchart
ProQR (PRQR) Rises on Expanding RNA-Editing Deal With Eli Lilly - Yahoo Canada Shine On
ASLAN Pharmaceuticals Stock Scheduled to Reverse Split on Wednesday, July 3rd (NASDAQ:ASLN) - Defense World
Financial Metrics Exploration: Understanding ASLAN Pharmaceuticals Ltd ADR (ASLN) Through Ratios – DWinneX - The Dwinnex
ASLAN Pharmaceuticals Ltd ADR (ASLN) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
ASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change - GlobeNewswire Inc.
Aslan Pharmaceuticals to Change Ratio to 1 ADS to 200 Shares - MarketWatch
U.S. shares mixed at close of trade; Dow Jones Industrial Average up 0.12% - MSN
New Strong Sell Stocks for June 8th - Yahoo Lifestyle Australia
All You Need to Know About ASLAN Pharmaceuticals (ASLN) Rating Upgrade to Buy - Zacks Investment Research
Here's Why ASLAN Pharmaceuticals (ASLN) Could be Great Choice for a Bottom Fisher - Zacks Investment Research
Post-Trade Analysis: ASLAN Pharmaceuticals Ltd ADR (ASLN) Slides -3.15, Closing at 0.43 – DWinneX - The Dwinnex
ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) Short Interest Update - Defense World
ProQR (PRQR) Rises on Expanding RNA-Editing Deal With Eli Lilly - Yahoo Movies Canada
ASLAN Pharmaceuticals Presents Late-Breaking Translational Data on Eblasakimab in COPD at the American ... - Investing.com India
ASLAN Pharmaceuticals Presents Late-Breaking Translational Data on Eblasakimab in COPD at the American Thoracic Society International Conference - GlobeNewswire Inc.
ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) Sees Large Growth in Short Interest - Defense World
ASLAN Pharmaceuticals (ASLN) Stock Forecast and Price Target 2024 - MarketBeat
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.62% - MSN
ASLAN Pharmaceuticals Excels in Eblasakimab TrialsTipRanks.com - TipRanks
ASLAN Pharmaceuticals to Present Additional Data From Interim Analysis of TREK-DX Phase 2 Study of Eblasakimab ... - Investing.com India
Eblasakimab Shows Promise for AD PatientsTipRanks.com - TipRanks
ASLAN Pharmaceuticals to Present Additional Data From Interim Analysis of TREK-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL Event - GlobeNewswire Inc.
ASLAN Pharmaceuticals to Host KOL Panel Discussion on Treatment Options for Atopic Dermatitis Patients With an Inadequate Response to Dupilumab - GlobeNewswire Inc.
ASLAN Pharmaceuticals (ASLN) Scheduled to Post Earnings on Friday - Defense World
Aslan Pharmaceuticals’ Eblasakimab Shows Promise - TipRanks
ASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients - GlobeNewswire Inc.
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Notice - GlobeNewswire Inc.
ASLAN Pharmaceuticals faces Nasdaq delisting over equity deficit - Investing.com
Aslan Pharmaceuticals Launches $12M ADS OfferingTipRanks.com - TipRanks
Are Medical Stocks Lagging ASLAN Pharmaceuticals (ASLN) This Year? - Zacks Investment Research
Aslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders - GlobeNewswire Inc.
symbol__ Stock Quote Price and Forecast - CNN
Is Aclaris Therapeutics (ACRS) Stock Outpacing Its Medical Peers This Year? - Zacks Investment Research
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.61% - Investing.com Australia
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.61% By Investing.com - Investing.com Canada
ASLAN Pharmaceuticals announces $5 million offering - Investing.com
U.S. shares mixed at close of trade; Dow Jones Industrial Average up 0.12% - Investing.com India
ASLAN Pharmaceuticals extends patent for alopecia drug By Investing.com - Investing.com
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.62% - Investing.com Canada
Valneva (VALN) Up on Antibody Persistence Data on Chikungunya Jab - Yahoo Lifestyle Singapore
Axsome (AXSM) Gains as Alzheimer's Agitation Study Meets Goal - Yahoo Singapore News
Aslan Pharma ADR earnings beat, Revenue Inline in Q2 - Investing.com India
The Daily Biotech Pulse: Novartis Funding For Gene Therapy Research, Priority Review For Amgen Cancer Drug, Pfizer-BioNTech Vaccine Supply Deal - Yahoo Finance
The Daily Biotech Pulse: Decision Day For Amgen, Zymeworks Sinks On Data, Ortho Clinical Diagnostics IPOiShares ... - Benzinga
ASLAN Pharma (NASDAQ:ASLN) Stock Quotes, Forecast and News Summary - Benzinga
Aslan's Rally Grows After Positive Readout From Eczema Drug StudyASLAN Pharma (NASDAQ:ASLN) - Benzinga
Aslan Dips Into Penny Stock Territory After Company Flunks Late-Stage Cancer StudyASLAN Pharma (NASDAQ - Benzinga
ASLAN Pharmaceuticals (ASLN) Stock Price, News & Analysis - MarketBeat
ADVFNFree stock and cryptocurrency prices, charts, market news and streaming real-time quotes. - ADVFN
大文字化:
|
ボリューム (24 時間):